Society for Immunotherapy of Cancer
The society of cancer immunologists and immuno-oncologists, whose annual meeting, guidelines and immune-related adverse event management resources track the immunotherapy era.
Founded in 1984 as the Society for Biological Therapy and renamed in 2010, SITC grew with checkpoint inhibitors into the main professional home of cancer immunotherapy. Its annual meeting each November presents cellular therapy, checkpoint, vaccine and bispecific data and translational immunology; it publishes the Journal for ImmunoTherapy of Cancer, issues Cancer Immunotherapy Guidelines by disease and on immune-related toxicities, and runs the Immuno-Oncology Biomarkers task forces, the Sparkathon early-career programme and the SITC Cancer Immunotherapy Winter School. SITC also produces the primer on CAR-T toxicity management and works with FDA on regulatory science for immunotherapy combinations.
- SITC Annual Meeting
- Journal for ImmunoTherapy of Cancer
- Cancer Immunotherapy Guidelines (disease and toxicity)
- Biomarker task forces
- Winter School and Sparkathon
Patrick Hwu is an immunotherapy pioneer who trained with Rosenberg and now leads Moffitt.
Immunologist who helped define the PD-1 pathway's role in cancer and built one of the largest immunotherapy institutes.
First author of the 2010 ipilimumab trial that proved immunotherapy could extend survival in melanoma.
Suzanne Topalian led the first nivolumab trials showing PD-1 blockade works across several cancers.
Pages like this
not linked directly; found by shared links- TermImmunotherapy
Shares Oncolytic viruses, TIL therapy, Immune-related adverse events (irAEs), Hot vs cold tumours.
- Key paperTopalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer
Shares Drew M. Pardoll, Suzanne L. Topalian, F. Stephen Hodi, Immune-related adverse events (irAEs).
- RoadmapImmunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity
Shares Oncolytic viruses, TIL therapy, Hot vs cold tumours, Personalised neoantigen (mRNA) vaccines.
- IdeaMake every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours
Shares Oncolytic viruses, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.
- Key paperASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors
Shares ICANS (neurotoxicity), Immune-related adverse events (irAEs), Cytokine release syndrome (CRS), American Society of Clinical Oncology (ASCO).
- IdeaClear the suppressive neutrophils out of pancreatic tumours first
Shares Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Immune checkpoint inhibitors.
- IdeaDe-acidify the tumour so T cells can work in it
Shares Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Immune checkpoint inhibitors.
- PathwayThe cancer-immunity cycle
Shares Oncolytic viruses, Hot vs cold tumours, Personalised neoantigen (mRNA) vaccines, T-cell engagers (bispecific).